Carl E. Brooks Joins Board At Inhibitex.

NORCROSS--(BW HealthWire)--March 2, 1999--

Joseph M. Patti, Ph.D., Director and Co-Founder, Named Chief

Scientific Officer

Inhibitex, Inc. today announced the election of Carl E. Brooks, President of Brooks & Associates of La Quinta, California, to its Board.

Brooks & Associates is a management consulting firm specializing in the biopharmaceutical industry, with particular expertise in marketing plasma fractionation and transfusion markets. With the election of Mr. Brooks, Inhibitex's Board now includes seven members. The Board also appointed Joseph M. Patti, Ph.D., Inhibitex's Vice President, Preclinical Development, as Chief Scientific Officer. Dr. Patti will continue to perform his duties as head of preclinical development in addition to his new role at the Company.

"As we approach our first clinical trial, I believe Carl's expertise in the development, manufacturing and marketing of plasma-derived products will immediately impact Inhibitex," stated William Johnston, Ph.D., President and Chief Executive Officer of Inhibitex. "In addition, his more than 20 years of biopharmaceutical development and marketing experience will assist us in implementing commercially driven, product-development programs."

"As a founder and co-inventor of Inhibitex's proprietary technology, Dr. Patti has already assembled a world-class team of researchers and collaborators focused on building Inhibitex's pipeline and dominant patent estate covering the Company's technology platform to treat antibiotic-resistant bacteria," continued Johnston. "In his expanded role as Chief Scientific Officer, Dr. Patti will also establish and oversee internal and collaborative research programs targeted at developing potential clinical and commercial candidates."

Prior to leading his own company, Mr. Brooks was President and Chief Executive Officer of Cryopharm Corporation, a biopharmaceutical company and leading developer of proprietary solutions and processes for the sterilization of human blood cells and tissues used in transfusion and transplantation. Before Cryopharm, he was President of the Hyland Division of Baxter International, Inc., in Glendale, California. The Hyland Division manufactured and marketed plasma derivatives with annual, worldwide sales in excess of $400 million and had more than 2,000 employees. Mr. Brooks earned his B.S. degree in chemical engineering from Ohio State University in Columbus, Ohio. Mr. Brooks is also a Board member of Millenium Health, Inc., in Santa Clara, California.

Joseph M. Patti, Ph.D., a co-founder of the Company, joined Inhibitex in 1998 as Vice President of Preclinical Development. Prior to his role at Inhibitex, Dr. Patti served as an Assistant Professor at the Institute of Biosciences and Technology, Texas A&M University at the Texas Medical Center in Houston. Dr. Patti was awarded his Ph.D. in Biochemistry from the University of Alabama at Birmingham.

In addition to Mr. Brooks and Dr. Patti, Inhibitex's Board includes: Michael Henos, Chairman of the Board, Managing Director, Alliance Technology Partners, Atlanta, Georgia; Magnus Hook, Ph.D., a co-founder of Inhibitex, Director of Extracellular Matrix Biology, Institute of Biosciences and Technology, Texas A&M University, Houston, Texas; Russell Medford, M.D., Ph.D., President and Chief Executive Officer, AtheroGenics, Inc., Norcross, Georgia; .T. Forcht Dagi, M.D., General Partner, Cordova Technology Partners, Atlanta, Georgia; and William Johnston, Ph.D., President and Chief Executive Officer, Inhibitex, Inc.

Inhibitex, Inc., is a therapeutics company focused on the discovery, development and commercialization of products from a proprietary technology platform for the infectious disease market. The Company's core technology is designed to inhibit bacterial adherence to host tissues, the first step in the initiation of infection. Inhibitex's leading programs focus on the development of antibody based products to prevent and treat infections caused by antibiotic resistant bacteria.